Isoprenoids in aging and neurodegeneration.
During aging the human brain shows a progressive increase in levels of dolichol, a reduction in levels of ubiquinone, but relatively unchanged concentrations of cholesterol and dolichyl phosphate. In a neurodegenerative disease, Alzheimer's disease, the situation is reversed with decreased levels of dolichol and increased levels of ubiquinone. The concentrations of dolichyl phosphate are also increased, while cholesterol remains unchanged. This study shows that the isoprenoid changes in Alzheimer's disease differ from those occurring during normal aging and that this disease cannot, therefore, be regarded as a result of premature aging. The increase in the sugar carrier dolichyl phosphate may reflect an increased rate of glycosylation in the diseased brain and the increase in the endogenous anti-oxidant ubiquinone an attempt to protect the brain from oxidative stress, for instance induced by lipid peroxidation.
Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
C
C
Edlund
M
M
Söderberg
K
K
Kristensson
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000502:physiology*; D000544:Alzheimer Disease / Q000378:metabolism; D000818:Animals; D001923:Brain Chemistry / Q000502:physiology*; D002478:Cells, Cultured; D002784:Cholesterol / Q000378:metabolism; D004288:Dolichol Phosphates / Q000378:metabolism; D004286:Dolichols / Q000378:metabolism; D006801:Humans; D050356:Lipid Metabolism; D008798:Mevalonic Acid / Q000378:metabolism; D008875:Middle Aged; D009410:Nerve Degeneration / Q000187:drug effects*; D011106:Polyisoprenyl Phosphates / Q000378:metabolism*; D051381:Rats; D014451:Ubiquinone / Q000378:metabolism
D004288:Dolichol Phosphates; D004286:Dolichols; D011106:Polyisoprenyl Phosphates; D014451:Ubiquinone; D002784:Cholesterol; D008798:Mevalonic Acid